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Abstract
Objectives: The clinical management of hepatocellular adenoma (HCA) and focal nodular hyperplasia
(FNH) is still subject to controversy, especially with respect to patient selection for surgery. The aim of this
prospective cohort study was to assess the outcomes of surgical intervention.
Methods: Between January 2008 and September 2012, patients diagnosed with FNH or HCA based on
magnetic resonance imaging or computed tomography were enrolled in this prospective study. Resection
was undertaken in patients with HCA of >5 cm or symptomatic lesions. Lesion characteristics, extent of
liver resection (minor: fewer than three segments; major: three or more segments), morbidity (by Dindo–
Clavien class), mortality, postoperative length of stay and symptoms [McGill Pain Questionnaire, including
a visual analogue scale (VAS)] were evaluated.
Results: A total of 110 patients (106 female; median age: 39 years) were included; 51 patients had HCA
and 59 had FNH. Of the 110 patients, 49 underwent resection (33 HCA patients; 16 FNH patients).
Laparoscopic minor resection was performed in five HCA and five FNH patients; open minor resection
was performed in 19 HCA and seven FNH patients, and open major resection was performed in nine HCA
and four FNH patients. Severe postoperative complications were observed in four patients (Grade III,
n = 3; Grade IV, n = 1). Median baseline scores on the VAS were 6 in FNH patients and 7 in HCA patients;
the median VAS score after resection was 0 (P = 0.008).
Conclusions: If patients with HCA and FNH require surgery, limited resection can be carried out with low
morbidity and without mortality. Patients with preoperative symptoms show a high rate of postoperative
symptom relief.
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Introduction
Whether liver surgery is indicated for benign liver lesions remains
controversial,1 particularly in hepatocellular adenoma (HCA) and
focal nodular hyperplasia (FNH). Both tumours are typically seen
in middle-aged women and are often incidental findings on
abdominal imaging studies.2 Because of the risk for bleeding and
malignant transformation, it is generally accepted that HCAs
measuring >5 cm in size should be resected.3–6 These risks do not
apply in FNH and surgery is therefore not indicated for FNH.7,8
However, patients may present with severe abdominal complaints
in the presence of a relatively small lesion or a lesion typical of
FNH on imaging, without other underlying causes for discomfort.
The issue of whether these complaints are correlated with the
lesion and outweigh the possible risks of intervention in such
patients creates a dilemma.
The diagnostic workup of HCA and FNH is based mainly on
cross-sectional imaging studies, of which magnetic resonance
imaging (MRI) and computed tomography (CT) are commonly
used to characterize lesions. The most sensitive method of
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differentiating HCA and FNH is MRI with hepatobiliary contrast
(Primovist® or MultiHance®).9–11 If imaging modalities are
inconclusive, a liver biopsy may be necessary to achieve a final
diagnosis.12
When a patient is considered for surgery, he or she should be
well informed and should ideally be included in a shared decision-
making process. Subjective symptoms and impact on daily life are
just as important as the statistics of surgical risks. Given these
dilemmas in clinical decision making, the present study was con-
ducted to assess the outcomes of surgical intervention in terms of
complications and the relief of symptoms in patients presenting
with lesions compatible with HCA or FNH.
Materials and methods
Patient population and diagnostic workup
Between January 2008 and September 2011, all consecutive
patients with suspected FNH or HCA of >2 cm based on imaging
studies were enrolled in this prospective study (follow-up ended
in September 2012). The local medical ethics committee approved
the study protocol and written informed consent was obtained
from all included patients.
Exclusion criteria were suspected (metastatic) malignant
disease and the presence of risk factors for malignant liver lesions,
including chronic hepatitis, cirrhosis, elevated a-fetoprotein
(a-FP) or carcinoembryonic antigen (CEA) in blood serum, and
pregnancy.
Standard of reference
Patients underwent MRI of the liver with Gd-EOB-DTPA (gado-
linium ethoxybenzyl diethylenetriamine pentaacetic acid; Primo-
vist®) using a 1.5-T MRI scanner (Avanto; Siemens Healthcare
AG, Munich, Germany). The dynamic contrast-enhanced T1-
weighted volumetric interpolated breath-hold examination
(VIBE) sequences were made at 30 s (arterial), 60 s (venous), 90 s
and 180 s (late) after i.v. bolus injection of 0.025 mmol/kg gadox-
etate disodium. Axial and coronal hepatobiliary phase images
were made at 20 min after injection using single breath-hold
sequences. The diagnosis of HCA was based on arterial enhance-
ment, with possible washout during the portal phase, the presence
of bleeding, fat or glycogen, and the absence of a central scar. The
diagnosis of FNH was based on the presence of a central scar,
arterial enhancement and the absence of signs of washout during
the portal phase of imaging. Finally, the lesions were evaluated for
signal intensity compared with surrounding liver tissue on the
T1-weighted hepatobiliary series at 20 min after injection. An iso-
intense or hyperintense signal status of the lesion was regarded as
diagnostic for FNH, and hypointensity was considered diagnostic
for HCA. Any MRI scans of lesions without these characteristics
were regarded as inconclusive. The largest lesion in each patient
was evaluated.
Until the MRI with Primovist® was proven sensitive for dif-
ferentiating HCA from FNH,11 a core biopsy of the lesion and
normal surrounding liver parenchyma was standard in this study
(using a 16-gauge needle, two lesional biopsies and one or two
normal liver tissue samples). The morphological characteristics
of HCA include hepatocellular proliferation without cytonuclear
atypia, with solitary arteries and the absence of portal tracts. A
well-developed reticulin framework is seen, without pseudoglan-
dular growth patterns. In addition to standard liver stainings,
including haematoxylin and eosin, collagen and CK7, additional
immunohistochemical staining was performed to classify
molecular subtypes of HCA.13 Morphological characteristics of
FNH include fibrotic strands, no nuclear atypia, and typical
map-like glutamine synthetase (GS) expression on immunohis-
tochemical staining. Halfway through 2011, the policy of stand-
ard biopsy was changed to one of biopsy only in the event of
inconclusive MRI findings in lesions of >5 cm with or without
symptoms.
Assessment of symptoms
Symptoms at the time of presentation (baseline) were assessed
using a questionnaire; this was re-administered at 6 months from
baseline or the intervention (second evaluation). The question-
naire was based on the validated McGill Pain Questionnaire14 and
its Dutch translation,15 and included a visual analogue scale (VAS)
with which to assess pain and discomfort, the number of words
count (NWC; S, sensory; A, affective; E, evaluation; NWC total),
and a pain rating index (PRI; S, sensory; A, affective; E, evaluation;
PRI total).
Treatment
Selective transarterial embolization (TAE) represented the treat-
ment of choice in patients presenting with haemodynamic insta-
bility caused by tumoral bleeding. Surgical treatment of HCA was
undertaken if the lesion was >5 cm. Smaller lesions were only
resected if the patient presented with persisting complaints which
could not be explained by other underlying causes including gall-
bladder, gastric, bowel, kidney or gynaecological conditions.
Depending on the patient’s history and the physical examination
and imaging findings already available, patients underwent addi-
tional endoscopy and/or colonoscopy, and abdominal imaging if
the standard workup for the liver did not cover other plausible
causes of discomfort. Focal nodular hyperplasia was only resected
if symptoms were severe (VAS scores of  7 for >6 months, with
the patient describing the complaint as ‘unbearable’ and ‘restric-
tive’ in daily life) and other possible causes of discomfort had been
investigated and excluded.
Liver resections were classified as major, defined as the resection
of three or more Couinaud’s segments, or minor; defined as the
resection of fewer than three liver segments, including enucleation
and (sub)segmental resections. Surgery was performed using
standard techniques. All major resections were performed in
an open procedure, whereas minor resections were performed
in open surgery or laparoscopically depending on the tumour’s
location.
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Tumour characteristics, type of liver resection, postoperative
morbidity (Dindo–Clavien class16) and mortality were recorded.
Statistical analyses
Statistical analysis was performed using IBM spss Statistics for
Windows Version 20 (IBM Corp., Armonk, NY, USA). Descriptive
statistics were used for the study population. The Mann–Whitney
U-test for medians was used to analyse continuous data. Pearson’s
chi-squared, Fisher’s exact and Spearman correlation tests were
used for categorical data analyses, including gamma and Somers’
D measures for ordinal by ordinal analyses.17 Statistical tests were
evaluated at the 5% level of significance.
Results
Patient population and standard of reference
A total of 120 patients with suspected HCA or FNH were initially
enrolled. Nine patients (8%) were given other diagnoses after an
initial diagnostic workup with MRI (haemangioma, n = 4, 3%;
hepatocellular carcinoma, n = 2, 2%; hamartoma, n = 2, 2%;
angiomyolipoma, n = 1, <1%). One patient with HCA (<1%)
withdrew during the diagnostic workup (Fig. 1). The remaining
110 patients were included in the study (Table 1).
Diagnosis was based on histopathological examination in 44
(86%) of the 51 patients with HCA (34/44 resection specimens;
10/44 biopsies) and 39 (66%) of the 59 patients with FNH (16/39
resection specimens; 24/39 biopsies). Because of sampling errors,
biopsy materials of four (8%) HCA and four (7%) FNH lesions
were not sufficient for diagnosis and diagnosis was therefore based
onMRI findings. The subclassification of HCA was undertaken in
10 biopsy and 34 resection specimens. Six samples appeared insuf-
ficient for additional immunohistochemical staining. Results in
the remaining 38 lesion samples showed inflammatory HCA in 20
lesions, steatotic HCA in eight lesions, and unclassified HCA in 10
lesions. No lesions were identified as being of the b-catenin
subtype. In three (6%) patients with HCA and 14 (24%) with
FNH, no histopathology was obtained and diagnosis was based on
MRI findings alone.
Imaging characteristics
A total of 105 patients underwent MRI of the liver; this showed
HCA in 45 (43%) patients (one of these 45 patients was misdiag-
nosed; histopathology revealed FNH) and FNH in 60 (57%)
patients. Two lesions showed discrepancies between the hepato-
biliary phase and dynamic series; the diagnosis of HCAwas incon-
clusive and corroborated by histopathology in these patients. In
one patient, MRI was inconclusive as a result of motion artefacts
and the diagnosis of HCA was based on histopathology. No MRI
was performed in four patients; two of these patients were claus-
trophobic and were diagnosed according to histopathology, and
two underwent CT imaging. Hepatic steatosis was seen in 29
(57%) of the 51 patients with HCA and in 12 (20%) of the 59
patients with FNH (P = 0.024).
Treatment
Results of treatment are summarized in Table 2. Conservative
treatment was delivered in 61 (55%) patients, including 18 (35%)
Included patients n = 110
Excluded patients
Haemangioma
Haemangioma n = 4
HCC n = 2
Hamartoma n = 2
Angiolipoma n = 1
Withdrawn  n = 1
Conservative n = 56
HCA n = 12
FNH n = 44
No follow-up    
Intervention n = 54
TAE n = 4
TAE + resection n = 4
Resection n = 46
(HCA 33, FNH 17)
Diagnostic workup n = 120
Figure 1 Flowchart of the study. HCC, hepatocellular carcinoma; TAE, transarterial embolization; HCA, hepatocellular adenoma; FNH, focal
nodular hyperplasia
142 HPB
HPB 2014, 16, 140–149 © 2013 International Hepato-Pancreato-Biliary Association
patients with HCA and 43 (73%) with FNH (P < 0.001). Eight
(16%) patients with HCA presented at the emergency room with
acute pain caused by bleeding of the lesion; these eight patients
were admitted, stabilized and subjected to selective TAE. One of
these eight patients underwent laparotomy within days of TAE
because of abdominal compartment syndrome and four under-
went elective resection of the lesion(s).
Resection was performed in 33 (65%) patients with HCA and
in 16 (27%) patients with FNH. Significantly more resections were
performed for HCA than for FNH (P < 0.001).
Figure 2 shows preoperative MRI, an intraoperative image and
postoperative MRI in a patient with HCA. Figure 3 shows preop-
erative MRI and intraoperative images in a patient with FNH.
Minor laparoscopic resection was performed in five (15%) of
the 33 HCA patients and in five (31%) of the 16 FNH patients
submitted to resection.Minor open resection was performed in 19
(58%) of the 33 HCA patients and in seven (44%) of the 16 FNH
patients. Major resection was performed in nine (27%) of the 33
HCA patients and in four (25%) of the 16 FNH patients. Postop-
erative length of stay (LoS) differed according to the type of
surgery performed. Significant differences in LoS were found
between patients undergoing laparoscopic and open surgery for
HCA (P = 0.013), laparoscopic andminor open resection for HCA
(P = 0.034), laparoscopic and open resection for FNH (P = 0.05),
and laparoscopic and minor open resection for FNH (P = 0.003).
However, no differences in postoperative LoS were seen between
patients undergoing minor open and major open resection for
either HCA or FNH (P = 0.740 and P = 0.263, respectively)
(Table 2).
Laparoscopic procedures took less time than open surgeries
(HCA: P = 0.005; FNH: P = 0.005). In HCA patients, open minor
resections took less time than open major resections (P < 0.001).
Complications after surgery occurred in both groups and
affected 11 of the 33 patients with HCA and seven of the 16
patients with FNH (P = 0.344). Grade I and II complications
were most common and were seen in 14 of the 18 patients with
complications.
Symptoms
In total, 34 of the 49 patients who underwent resection reported
abdominal complaints prior to surgery. Symptoms were relieved
in 30 of these 34 patients after surgery (Table 3). Symptoms are
summarized in Tables 3 and 4.
Table 1 Characteristics of patients in the study population (n = 110)
Sex, male/female, n 4/106
Age, years, median (range) 39 (19–72)
Diagnosis HCA FNH P-value
Patients, n (%) 51 (46%) 59 (54%)
Size, cm, median (range) 6.5 (2.2–25.0) 5.5 (2.0–12.6) 0.828
Liver function test, n (%)
Unknown 0 4
Normal 14 (27%) 30 (51%)
Abnormal 36 (72%) 26 (46%) 0.019
AST, U/l (normal < 40 U/l), median (range) n = 4, 55 (50–110) n = 1, 41 (NA) 0.400
ALT, U/l (normal < 45 U/l), median (range) n = 7, 82 (50–128) n = 3, 59 (48–85) 0.517
a-FP, U/l (normal < 120 U/l), median (range) n = 11, 226 (129–466) n = 5, 141 (122–258) 0.180
g-GT, U/l (normal < 60 U/l), median (range) n = 15, 101 (62–369) n = 10, 148 (70–774) 0.015
Lesions, n (%)
Solitary 14 (27%) 31 (53%) 0.011
2–5 21 (41%) 28 (47%) 0.507
6–9 3 (6%) 0 0.074
 10 12 (24%) 0 <0.001
Undetected post-bleeding 1 (2%) 0
Location, n (%)
Left liver 22 (43%) 27 (46%) 0.782
Right liver 29 (57%) 32 (54%)
HCA, hepatocellular adenoma; FNH, focal nodular hyperplasia; NA, not applicable; AST, aspartate aminotransferase; ALT, alanine transaminase; a-FP,
a-fetoprotein; g-GT, g-glutamyl transferase.
Overall, liver function tests were more often abnormal in HCA in comparison with FNH; median g-GT was significantly higher in patients with HCA than
in patients with FNH. Lesions were often solitary in FNH, whereas HCA more often showed multiple lesions. Locations of the lesions throughout the
liver were similar across both patient groups.
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The pain questionnaire was completed by 48 (94%) of the 51
patients with HCA. Pain categories present in at least one third of
the patients with HCA and FNH are shown in Table 4. Specific to
HCA rather than to FNH was ‘drilling’ (P = 0.045). Specific pain
categories reported by the eight patients who submitted to emer-
gency TAE but not by HCA patients who did not undergo emer-
gency TAE included ‘shooting’ (P = 0.044), ‘lacerating’ (P =
0.032), ‘crushing’ (P = 0.034), ‘splitting (P = 0.001) and ‘wrench-
ing’ (P = 0.023) pain. The NWC was higher in the emergency
TAE patient group than in the entire HCA patient group
(Sensory: P = 0.009; Affective: P = 0.026; Evaluation: P = 0.005;
Total: P = 0.011), as was the PRI (Sensory: P = 0.001; Affective:
P = 0.036; Evaluation: P = 0.033; Total: P = 0.015). No differences
in the NWC and PRI were found between patients with HCA or
Table 2 Treatment of hepatocellular adenoma (HCA) and focal nodular hyperplasia (FNH). Overall, 65% of patients with HCA and 27% of
patients with FNH underwent resection, with surgical timea and postoperative length of stayb in the laparoscopic patient group significantly
lower than in the open procedures group
Hepatocellular adenoma (n = 51)
Conservative treatment, n (%) 18 (35%)
Size, cm, median (range) 5.4 (2–10)
Transarterial embolization, n 9
Emergency care (bleeding), n (%) 6 (12%)
Preventive care, n (%) 3 (6%)
Overall Laparoscopic Open minor Open major P-value
Resection
Patients, n (%) 33 (65%) 5 19 9
Size, cm, median (range) 7 (3–25) 8.4 (6–11) 7.4 (3–13) 7 (6–25)
ASA classification, n
ASA 1 17 3 9 5
ASA 2 15 2 9 4
ASA 3 1 0 1 0
Surgical time, min, median (range) 175 (58–406) 100a (69–144) 170 (58–231) 226 (200–406) 0.005a
Postoperative LoS, days, median (range) 7 (2–13) 5b (2–7) 7 (3–13) 7 (5–11) 0.013b
Complications, n
None 22 2 14 6
Grade I or II 10 3 5 2
Grade III 1 0 0 1
Focal nodular hyperplasia (n = 59)
Conservative treatment, n (%) 43 (73%)
Size, cm, median (range) 6 (2–11)
Overall Laparoscopic Open minor Open major P-value
Resection
Patients, n (%) 16 (27%) 5 7 4
Size, cm, median (range) 6.2 (3–126) 4 (3–7) 5.8 (4–12) 8.6 (7–13)
ASA classification, n
ASA 1 9 3 3 3
ASA 2 7 2 4 1
ASA 3 0 0 0 0
Surgical time, min, median (range) 144 (62–267) 94a (62–107) 161 (58–231) 202 (100–267) 0.005a
Postoperative LoS, days, median (range) 6 (2–22) 4b (2–5) 7 (5–9) 7 (6–22) 0.05b
Complications, n
None 9 5 2 2
Grade I or II 4 0 3 1
Grade III or IV 3 0 2 1
ASA, American Society of Anesthesiologists physical status classification system; LoS, length of stay.
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FNH when corrected for patients who underwent emergency
TAE (P = 0.775).
Discussion
This prospective study of outcomes of treatment of HCA and
FNH shows that resection of the lesion(s) is safe and results in the
relief of complaints in the majority of symptomatic patients with
HCA or FNH. No mortality occurred and most postoperative
complications were minor according to the Clavien–Dindo clas-
sification (Grade I or II). These findings are in accordance with a
previous publication from the present authors’ institution,
showing that liver resection for benign hepatobiliary lesions was
not associated with mortality and resulted in less morbidity than
it did in patients undergoing resection for malignancies.18
Because HCA and FNH are benign tumours, limited resections
usually suffice to remove all tumour tissue.Most of these tumours
are amenable to parenchyma-sparing techniques. For example,
lesions located in segment I allow the isolated resection of
segment I, as was performed in three patients in the present
series.19 Of note are the blood transfusions required for minor
resections in this series (two patients). Both HCA and FNH are
hypervascular tumours and thus, in dissection, many blood
vessels that traverse the interface between tumour and surround-
ing liver parenchyma are encountered. Enucleation of the tumour,
therefore, may result in considerable blood loss. In the authors’
experience, the use of the Cavitron® Ultrasonic Surgical Aspirator
(CUSA®), in combination with a Pringle manoeuvre, enables the
surgeon to follow the plane between the tumour and adjacent
parenchyma and to manage the blood vessels selectively. In addi-
tion, non-anatomical resections may result in longer dissection
times and larger wound surfaces, both of which contribute to
greater blood loss during the procedure.
Although both HCA and FNH are benign hepatic lesions, asso-
ciated findings are quite different, as this study shows. Patients
with HCA more often had elevated serum liver function tests
(a) (b)
(c) (d)
Figure 2 Imaging of hepatocellular adenoma (HCA). (a) Transverse magnetic resonance imaging (MRI) in the arterial phase with Primovist®
shows a hyperintense lesion (arrow) in the centre of the liver. (b) In the hepatobiliary phase of scanning no uptake of contrast is seen within
the lesion (arrow), which is consistent with HCA. (c) At laparotomy, the lesion is enucleated to minimize the loss of healthy liver parenchyma
(arrow). (d) A few months after surgery, MRI shows a hypointense area where the lesion used to be, consistent with postoperative changes
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(72%), hepatic steatosis (57%) and multiple lesions. Eight of the
patients with HCA presented at the emergency room with acute
pain caused by the bleeding of the lesion, whereas none of the
patients with FNH needed emergency care. Significantly more
resections were performed in HCA than in FNH patients.Without
intervention, patients with HCA showed symptom relief over
time. The differences between the groups may in part be explained
by the occurrence of bleeding in HCA: some bleeding in HCA will
need emergency intervention, and part of the discomfort caused
by bleeding HCA will subside over time as the haematoma is
absorbed.
This study showed not only differences between the types of
hepatic lesion, but also similarities. Resection of HCA and FNH
resulted in the relief of symptoms in both groups. These results are
in line with those reported by Perrakis et al., who noted relief in
95% of symptomatic patients with HCA.3 Patients with lesions in
the left lateral segments that give rise to abdominal complaints
and additional gastric complaints benefit particularly from
surgery, which can achieve complete symptom relief. Gastric com-
plaints could not be explained by any causes other than the lesion
in the left liver. However, in the present study, size was not corre-
lated with symptoms. This probably reflects some degree of selec-
tion bias as patients with abdominal complaints will seek medical
attention and those without will present only if the lesion is found
incidentally. The high rate of resections for FNH is also explained
by this selection bias as patients with severe complaints will seek
medical assistance and will be more persistent in their wish for
(even invasive) treatment. Complications in FNH are rare and are
cited only in case reports.20 Assessing the severity of symptoms
and whether these originate from the detected liver lesion remains
difficult. Abdominal pain or discomfort can have a number of
other causes, which should be ruled out before surgery is planned.
When feasible, a laparoscopic resection is preferred over an
open procedure, especially for lesions in the left or anterior liver
(a) (b)
(c) (d)
Figure 3 Imaging of focal nodular hyperplasia (FNH). (a) Transverse magnetic resonance imaging (MRI) in the arterial phase with Primovist®
shows a large, slightly hyperintense lesion (arrow), with a hypodense centre, in the right liver, consistent with a central scar (arrowhead). (b)
The central scar is more prominent in the hepatobiliary phase of scanning and the lesion is isointense in comparison with the surrounding
liver parenchyma, which is consistent with FNH. (c) At laparotomy, the lesion protrudes from the liver and (d) can be removed with minimal
damage to the liver parenchyma
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segments. It is well documented that the postoperative LoS is
shorter after laparoscopic surgery and, particularly in this young
and mainly female group of patients, the cosmetic result plays
an important role.21 However, the feasibility of a laparoscopic
approach should not influence perceptions of indications for
resection.
Few treatment options other than surgical intervention have
been proposed. Percutaneous radiofrequency ablation (RFA) has
been performed for HCA and FNH with good results and cost-
efficiency ratios.22,23 However, the procedure is limited by the loca-
tion and size of the tumour. It is possible that residual tumour
tissue is less problematic in a benign tumour. In the treatment of
lesions of < 3 cm, RFA is a good treatment option and, depending
on the location of the lesion,may even be selected as the treatment
of choice. Further research should determine the longterm out-
comes and limitations of RFA in the ablation of HCA and FNH.
At the present authors’ institution, TAE is considered the first-
line treatment modality when a patient presents with massive
bleeding and rupture of a hepatic tumour, including HCA.24,25
Through the close collaboration of a skilled interventional radi-
ologist and surgeon, laparotomy can be avoided in these emergen-
cies. The technique can also be used as a minimally invasive,
preventive intervention that hypothetically decreases the risk for
future bleeding; it was applied in this study in an HCA patient
who was a Jehovah’s Witness. As yet, no data are available on
tumour behaviour after TAE, including the risk for malignant
transformation of the remaining adenomatous tissue.
Based on the findings of the present study and the available
literature, the present authors propose the following approach
should be taken in patients with HCA and FNH. Diagnostic
workup should include hepatobiliary contrast MRI.11 In patients
diagnosed with FNH, resection is advised only if abdominal com-
plaints are severe and other causes of symptoms have been
excluded. All patients with HCA should discontinue oral contra-
ceptives. Until risk analyses during pregnancy have been properly
studied, all patients should undergo close follow-up during preg-
nancy.26 Hepatocellular adenoma in male patients and of >5 cm in
female patients should be resected.5 Liver adenomatosis is an arbi-
trary diagnosis when more than nine HCA lesions (whatever their
size) are found, but in the present authors’ practice, it is not an
indication for liver transplantation. Patients are treated according
to the sizes of lesions and the presence of bleeding and symptoms,
like any other patient with HCA. In addition, HCA lesions of <
5 cm in size, and FNH lesions, if severely symptomatic, can be
considered for resection after other possible causes of abdominal
complaints have been evaluated.
Future studies should determine whether different subtypes of
HCA carry different profiles of risk for bleeding, recurrence
(however small the risk) and malignant transformation. Subtype
classification, however, requires the obtaining of biopsy material
of the lesion, which is subject to sampling errors. Improvements in
MRI techniques may play a role in the non-invasive assessment of
these subtypes and facilitate the more accurate selection of
patients who will benefit from surgery.
In conclusion, if patients with HCA and FNH require surgery,
limited resection can be carried out with low morbidity and
without mortality. Patients with preoperative symptoms show a
high rate of postoperative symptom relief.
Table 3 Visual analogue scale (VAS), symptoms and presentation
Presentation Hepatocellular adenoma (n = 51) Focal nodular hyperplasia (n = 59)
Patients, n (%) VAS score,
median (range)
P-value Patients, n (%) VAS score,
median (range)
P-value
Incidental finding 20 (39%) 27 (46%)
Symptomatic 31 (61%) 7 (2–10) 32 (54%) 6 (1–10)
Gastric complaints 6 (12%) 11 (19%)
Left liver 5/22 0.044 10/28 0.004 6 (0–9) 0.008
Right liver 1/29 2/31 0 (0–9)
Treatment
TAE emergency care 8 8 (5–10) 0.005 NA
TAE preventive care 2
No TAE 41 1 (0–10) NA
No resection 18 (35%) 43 (73%)
Baseline 0 (0–10) 0.013 0 (0–8) <0.001
Follow-up 0 (0–7) 0 (0–8)
Resection 33 (65%) 16 (27%)
Baseline 7 (0–10) 0.008 6 (0–10) 0.008
Follow-up 0 (0–8) 0 (0–7)
TAE, transarterial embolization; NA, not applicable.
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Table 4 Pain categories and indexa14,15,27
Common categories
( 33% of patients)
Hepatocellular adenoma (n = 48) Focal nodular hyperplasia (n = 57)
NWC PRI NWC PRI P-value
1 Flickering, flashing, shooting 12 25 10 21 0.754
TAE (n = 8): shooting 4 9 0.044
3 Pricking, boring, drilling 23 51 22 42 0.045
4 Sharp, cutting, lacerating 20 34 20 36 0.886
TAE (n = 8): lacerating 6 10 0.032
5 Pinching, pressing, crushing 24 38 26 39 0.650
TAE (n = 8): crushing 5 9 0.034
6 Tugging, pulling, splitting 13 20 12 20 0.086
TAE (n = 8): splitting 5 8 0.001
10 Tight, squeezing, wrenching 19 48 19 51 0.791
TAE (n = 8): wrenching 5 11 0.023
12 Dull, gnawing, persisting 22 39 28 46 0.746
Total sensory 1–7, median (range) 3 (0–12) 5 (0–33) 2 (0–12) 2 (0–30) NWC, 0.781
PRI, 0.821
TAE (n = 8) total sensory, median (range) 7 (6–10) 15 (8–22) NWC, 0.009
PRI, 0.001
13 Tiring, arduous, exhausting 26 48 29 47 0.897
14 Cranky, disconsolating, depressing 13 28 14 27 0.668
15 Tense, suffocating, sickening 19 32 21 36 0.370
16 Fearful, frightful, terrifying 19 34 20 36 0.066
Total affective 13–16, median (range) 1 (0–5) 2 (0–15) 1 (0–5) 1 (0–15) NWC, 0.486
PRI, 0.113
TAE (n = 8) total affective, median (range) 4 (1–5) 5 (1–12) NWC, 0.026
PRI, 0.036
18 Light, moderate, bad, severe 21 58 27 68 0.675
19 Bearable, troublesome, intense, unbearable 23 59 28 57 0.012
20 Bothersome, gruelling, vicious, killing 22 44 27 46 0.796
Total evaluation 18–20, median (range) 1 (0–3) 1 (0–12) 0 (0–3) 0 (0–12) NWC, 0.237
PRI, 0.260
TAE (n = 8) total evaluation, median (range) 3 (2–3) 6 (3–10) NWC, 0.005
PRI, 0.021
Overall, median (range) 6 (0–20) 10 (0–59) 4 (0–20) 6 (0–56) NWC, 0.851
PRI, 0.545
TAE overall, median (range) 13 (10–18) 22 (16–44) NWC, 0.011
PRI, 0.015
NWC, number of words count; PRI, pain rating index; TAE, transarterial embolization.
The first 12 categories are ‘sensory’ categories. 12 categories means a maximum score of 12 NWC per patient and every count has three severity
gradations: mild, intermediate and severe. The maximum PRI is therefore 3 ¥ 12 = 36 per patient. Categories 13–16 are ‘affective’ categories, with
a maximum NWC of 4 per patient and maximum PRI of 4 ¥ 3 = 12 per patient. The final categories 17–20 are ‘evaluation’ categories, with a maximum
NWC of 4 and maximum PRI of 4 ¥ 4 = 16 per patient. Total NWC and PRI are given for each group of categories, and for all categories combined
(sensory, affective and evaluation; median and range per patient).
Patients in need of emergency TAE have a different pain pattern compared with HCA patients who are not in need of emergency care, with a higher
NWC and PRI in all categories.
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